Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Other, Topics Oct 22 | 2024Noom Partners With Waltz for GLP-1RAs; Seraxis Initiates Islet Cell Trial; Madrigal Completes MASH Outcomes Trial EnrollmentPurchase Blast
$599
Posted in: GLP-1RA, SGLT2i, Topics Oct 21 | 2024Novo Oral Semaglutide T2DM CVOT Data; Lilly Ph3 Orforglipron OSA Trial; Additional Calls to Block Novo-Catalent Acquisition; Lilly Partners for Obesity Awareness; Biomea Names BMF-219 “Icovamenib”Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Oct 17 | 2024Lilly initiates Bimagrumab+Tirzepatide trial; Lexicon and Viatris Partner for Sotagliflozin Commercialization; Gan & Lee T2DM Assets Meet Primary Endpoints; Lipocine Virtual KOL Event; Noom Adds Body Composition to AppPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 16 | 2024Abbott Q3 ’24 Earnings; Neurogastrx’s NG101 Reduces GLP-1RA-Related AEs; Kaleido Insulin Pump Receives CE Mark; Alnylam Submits Vutrisiran to EMAPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 15 | 2024Adocia Patents Semaglutide + Cagrilintide Combination; Seraxis Receives IND for Islet Cell Study; Upcoming AASLD 2024 PresentationsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 14 | 2024FDA Tirzepatide Shortage Removal Update; Catalent Sells Site to Ardena; LifeVantage Launches MindBody GLP-1 System; Inventiva Receives Additional Funding for MASH; October CHMP Agenda; Sagimet Publishes FASCINATE-2 Data; Q Bio Appoints Jeff Brewer as CEOPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 10 | 2024Senator Warren Calls for Novo/Catalent Block; Lilly Sends Cease-And-Desist to Compounding Pharmacies; Lilly and KeyBioscience Continue Obesity CollaborationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 09 | 2024Zealand Receives Second CRL; Lilly Partners for Drug Discovery and Peptide R&D; Alnylam Submits Vutrisiran sNDA; BI Initiates Two Survodutide TrialsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Oct 08 | 2024BI Receives BTD for Survodutide and Initiates 2 Ph3 MASH Trials; Roche Ph2 CT-388 Trial in Obesity+T2DM; Drug Compounder Group Sues FDA; WeightWatchers to Offer Compounded Semaglutide; Novo Invests $158M in Insulin PlantPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Oct 08 | 2024AZ Lp(a) Licensing Deal; Novo Reaches Semaglutide Patent Settlement with Viatris; Trinity Completes Pre-Pivotal CGM TrialPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Oct 04 | 2024Elevai Files Patents For Obesity Lean Mass Preservation; Medtronic Pump RecallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Oct 03 | 2024FDA Removes Tirzepatide from Shortage ListPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 02 | 2024Eversense 365 Launched in US; Kailera Launches as Obesity Biotech; Lilly Founds New $4.5B Indiana FacilityPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 01 | 2024Metsera Partners with Amneal for Obesity Manufacturing; Rivus Obesity Data at HFSA 2024; Sagimet Receives BTD for Denifanstat; Biomea Establishes Scientific Advisory Board; Madrigal Appoints New SVPPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 01 | 2024Roche Pharma Day; Rezdiffra QoL Publication; Pemvidutide Trial Enrollment Updates; NeuroBo Ph1 Obesity Readout; MannKind Afrezza DataPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 27 | 2024FDA Lifts BMF-219 Clinical Hold; Abvance ABV 101 Virtual KOL EventPurchase Blast
$599
Posted in: Other, Topics Sep 26 | 2024Novo and Evotec Partner for Cell Therapy Development; J&J Divests CVRM PortfolioPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 25 | 2024Galmed MASH Open-Label Publication; Entera/OPKO GLP-1/GCG Pre-Clinical UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 24 | 2024Metsera Reports Positive Ph1 Obesity Topline Results; Novo CEO Testifies at Senate HELP Committee HearingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 23 | 2024Skye Defends Nimacimab After Disappointing Novo Obesity Data; Sanofi Invests in Obesity Asset; Arrowhead Files to Initiate ARO-INHBE Obesity StudyPurchase Blast